SEMG-1 expression in early stage chronic lymphocytic leukemia

References

• Ribera JM, Vinolas N, Urbaon-Ispizua A, Gallart T, Montserrat E, Rozman C. ‘Spontaneous’ complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature. Blood Cells. 1987; 12: 471–83
   PubMedGoogle Scholar
• Ziegler-Heitbrock HW, Schlag R, Flieger D, Thiel E. Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood. 1989; 73: 426–30
   Google Scholar
• Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Bruggemann M, Pott C, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measured with quantitative PCR. Blood. 2004; 104: 2600–2
   PubMed Web of Science ®Google Scholar
• Gitelson E, Hammond C, Mena J, Lorenzo M, Buckstein R, Berinstein NL, et al. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res. 2003; 9: 1656–65
   PubMed Web of Science ®Google Scholar
• Goddard RV, Prentice AG, Copplestone JA, Kaminski ER. Generation in vitro of B-cell chronic lymphocytic leukemia-proliferative and specific HLA class II-restricted cytotoxic T-cell response using autologous dendritic cells pulsed with tumour cell lysate. Clin Exp Immunol. 2001; 126: 16–28
   PubMed Web of Science ®Google Scholar
• De Lamirande E, Yoshida K, Yoshiike TM, Iwamoto T, Gagnon C. Semenogelin, the main protein of semen coagulum, inhibits human sperm capacitation by interfering with the superoxide anion generated during this process. J Androl. 2001; 22: 672–9
   PubMedGoogle Scholar
• Ulvsback M, Lazure C, Lilja H, Spurr NK, Rao VV, Loffler C, et al. Gene structure of semenogelin I and II. The predominant proteins in human semen are encoded by two homologous genes on chromosome 20. J Biol Chem. 1992; 267: 18080–4
   PubMedGoogle Scholar
• Asimakopoulos FA, White NJ, Nacheva E, Green AR. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood. 1994; 84: 3086–94
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Liu H, Giles FJ, Lim SH. Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies. J Immunother. 2003; 26: 461–7
   PubMedGoogle Scholar
• Lundwall A, Giwercman A, Ruhayel Y, Giwercman Y, Lilja H, Hallden C, et al. A frequent allele codes a truncated variant of semenogelin 1, the major protein component of human semen coagulum. Mol Human Reprod. 2003; 9: 345–50
   PubMedGoogle Scholar
• Ravandi F, O'Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006; 55: 197–209
   PubMed Web of Science ®Google Scholar
• Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. 2003; 63: 4497–506
   PubMed Web of Science ®Google Scholar
• Norris DA, Weston WL, Tubergen DG, Rose B, Odom LF. Monocyte chemotaxis in leukemia patients. J Lab Clin Med. 1980; 95: 609–15
   PubMedGoogle Scholar
• Foa R, Fierro MT, Lusso P, Raspadori D, Ferrando ML, Matera L, et al. Reduced natural killer T-cells in B-cell chronic lymphocytic leukemia identified by three monoclonal antibodies: Leu-11, A10, AB8.28. Br J Haematol. 1986; 62: 151–4
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Y, Mandal A, Zhang J, Giles FJ, Herr JC, et al. The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies. Clin Cancer Res 2004; 10: 6544–50
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Y, Liu HC, Chiriva-Internati M, Lim SH. Gene expression and immunologic consequence of SPAN-X in myeloma and other hematologic malignancies. Blood. 2003; 101: 955–60
   PubMed Web of Science ®Google Scholar
• Cooper CD, Liggins AP, Ait-Tahar K, Roncador G, Banham AH, Pulford K. PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia. 2006; 20: 2172–4
   PubMed Web of Science ®Google Scholar
• Proto-Siqueira R, Falcao RP, de Souza CA, Ismael SJ, Zago MA. The expression of PRAME in chronic lymphoproliferative disorders. Leuk Res. 2003; 27: 393–6
   PubMedGoogle Scholar
• Zhang Y, Wang Z, Zhang J, Farmer B, Lim SH. Semenogelin I expression in myeloma cells can be upregulated pharmacologically. Leuk Res. 2008; 32: 1889–94
   PubMedGoogle Scholar